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Brigatinib combined with anti-EGFR
antibody overcomes osimertinib resistance
in EGFR-mutated non-small-cell lung cancer
Ken Uchibori1,2, Naohiko Inase2, Mitsugu Araki3, Mayumi Kamada4, Shigeo Sato1, Yasushi Okuno3,4,
Naoya Fujita1 & Ryohei Katayama1
Osimertinib has been demonstrated to overcome the epidermal growth factor receptor
(EGFR)-T790M, the most relevant acquired resistance to ﬁrst-generation EGFR–tyrosine
kinase inhibitors (EGFR–TKIs). However, the C797S mutation, which impairs the covalent
binding between the cysteine residue at position 797 of EGFR and osimertinib, induces
resistance to osimertinib. Currently, there are no effective therapeutic strategies to overcome
the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR–TKI resistance.
In the present study, we identify brigatinib to be effective against triple-mutation-harbouring
cells in vitro and in vivo. Our original computational simulation demonstrates that brigatinib
ﬁts into the ATP-binding pocket of triple-mutant EGFR. The structure–activity relationship
analysis reveals the key component in brigatinib to inhibit the triple-mutant EGFR. The
efﬁcacy of brigatinib is enhanced markedly by combination with anti-EGFR antibody because
of the decrease of surface and total EGFR expression. Thus, the combination therapy of
brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR.
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on-small-cell lung cancer (NSCLC) harbouring an
epidermal growth factor receptor (EGFR)-activating
mutation accounts for B30–40% of NSCLC in the
Japanese population and B15% in Caucasians1. For the
treatment of EGFR-mutated NSCLC, EGFR–tyrosine kinase
inhibitors (EGFR–TKIs) that inhibit the EGFR-induced
downstream signalling pathway by binding to the ATP-binding
pocket of the EGFR–tyrosine kinase domain have been evaluated
and are currently being clinically used2–9. The use of EGFR–TKIs
has improved prognoses in patients with EGFR-mutated lung
cancer10.
Before clinical application of EGFR–TKIs, the overall survival
of NSCLC patients was only approximately a year, as shown in
the trials verifying the efﬁcacy of platinum doublets chemother-
apy in metastatic NSCLC11. Several clinical trials of EGFR–TKIs
in EGFR-activating mutation-positive NSCLC patients have
shown improved survival of 2 to nearly 3 years12–14. The
importance of treatment with the appropriate molecularly
targeted drugs in driver oncogene-positive NSCLC has been
increasingly recognized. Kris et al.15 reported the beneﬁt of
precisely identifying the target oncogenes in cancer cells and
providing the appropriate molecularly targeted therapy.
Although the beneﬁts of molecularly targeted drugs are
substantial, most patients experience a recurrence of disease within
B1–2 years due to acquired resistance. The acquired resistance
against the ﬁrst-generation EGFR–TKIs geﬁtinib and erlotinib has
been revealed to be mainly caused by a gatekeeper mutation16,17
involving substitution of threonine at position 790 with methionine
(T790M), which hampers the binding of the EGFR–TKI to the
ATP-binding site of EGFR and accounts for 60–70% of resistant
cases18,19. Many clinical trials of various agents to overcome
the acquired resistance to geﬁtinib or erlotinib were tried but
failed to show any clinical advantage, except for one trial in
which afatinibþ cetuximab achieved a response rate of 29%
(refs 20–25). Despite its efﬁcacy, this combination treatment
has not been used in the clinical setting because of its relatively
severe toxicity. To resolve this difﬁcult situation, covalently
binding third-generation EGFR–TKIs selectively targeting
T790M have been evaluated for the treatment of patients with
advanced EGFR-mutated NSCLC26–28. Osimertinib, which was
reported to be efﬁcacious in T790M mutation-positive EGFR-
mutated NSCLC29, has been approved in the US and other
countries. Ja¨nne et al.30 reported that in a phase 1/2 trial
of osimertinib, among 127 patients with conﬁrmed EGFR
T790M who could be evaluated, the response rate was 61% and
the median progression-free survival was 9.6 months, which is as
long as that of ﬁrst-line EGFR–TKIs for EGFR-mutated lung
cancer.
Approval of osimertinib will inﬂuence the treatment tactics for
EGFR-mutated lung cancer, but, again, resistance to osimertinib
will be a major obstacle. In 2015, various mechanisms of the
acquired resistance against osimertinib were independently
published by several groups. An EGFR mutation involving
substitution of cysteine at position 797 with serine (C797S) was
detected in cell-free plasma DNA from osimertinib-refractory
patients and was shown to induce osimertinib resistance31.
Ercan et al.32 reported that Ba/F3 cells with three amino acid
substitutions, L844V, L718Q and C797S, found using the
N-ethyl-N-nitrosourea mutagenesis method, are totally
refractory to the third-generation EGFR–TKIs WZ-4002,
osimertinib and CO-1686. In cases without the C797S
mutation, although loss of T790M was reported as speciﬁc
resistant mechanism to third-generation EGFR–TKIs, bypass
pathway activation, such as c-MET activation or small-cell lung
cancer (SCLC) transformation, in resistant tumours is thought
to be the mechanism of resistance similar to that known in
ﬁrst-generation EGFR–TKIs33–39. Indeed, HER2 ampliﬁcation,
Met ampliﬁcation, BRAF mutation and SCLC transformation
have been observed in osimertinib-resistant cases40,41. Therefore,
new therapeutic strategies are needed to overcome the resistance
to the third-generation EGFR–TKIs.
The osimertinib resistance due to the loss of T790M or bypass
pathway activation is expected to be overcome using existing
methods, for example, exchange to or addition of a ﬁrst-
generation EGFR–TKI or concurrent combination therapy of
an inhibiting alternative pathway, respectively. However, we now
have no clinically available strategy to conquer the C797S/
T790M/activating-mutation (triple-mutation). Recently, Jia
et al.42 published a unique allosteric EGFR inhibitor that can
overcome the EGFR–TKI resistance by EGFR-C797S/T790M/
L858R mutation, but not EGFR-C797S/T790M/del19-mediated
resistance by treating in combination with cetuximab. Niederst
et al.43 investigated the emergence of the C797S allele and found
that if C797S developed in trans of the T790M allele, a
combination of ﬁrst- and third-generation EGFR–TKIs may be
effective enough for clinical use; however, when the C797S and
T790M mutations developed in cis, all sensitivity to any of the
existing EGFR–TKIs, including the third-generation ones, was
lost. However, we currently have no information on whether the
in vitro efﬁcacy of the combination of ﬁrst- and third-generation
EGFR–TKIs for trans C797S is clinically reproducible. The C797S
mutations found in the samples obtained from participants in the
osimertinib trial mentioned above were all in cis alleles except for
one case of in trans31. The frequency of resistance caused by
C797S emergence is not well known because of the small number
of third-generation-resistant patients, but the importance of
developing treatment strategies for this group will be increasing
in the near future as more and more patients with EGFR-mutated
NSCLC will be receiving osimertinib.
To investigate the therapeutic strategies for treating patients
with triple-mutant EGFR, we performed drug screening and
found brigatinib to be the promising candidate against triple-
mutant EGFR with less potency against wild-type EGFR
according to the in vitro and in vivo assays. Structure–activity
relationship analysis and computational simulation reveal the key
component determining the afﬁnity and the binding mode to
triple-mutant EGFR that are expected to attribute to the future
development. Finally, the combination with anti-EGFR antibody
strikingly reduces the IC50 of brigatinib and prolongs the survival
of the triple-mutant EGFR xenograft-bearing mice. These
ﬁndings in this study may help overcome acquired resistance to
third-generation EGFR–TKIs.
Results
Drug resistance by EGFR-C797S/T790M/activating mutations.
Currently, there are four EGFR–TKIs available in the clinical
setting—geﬁtinib, erlotinib, afatinib and osimertinib. Geﬁtinib
and erlotinib are so-called ﬁrst-generation EGFR–TKIs that were
proven to be efﬁcacious for NSCLC harbouring an EGFR muta-
tion (EGFR-activating mutation; exon 19 deletion [del19] or
L858R point mutation in exon 21 [L858R]). Afatinib is a second-
generation EGFR–TKI irreversibly targeting the pan-HER signal
pathway. Osimertinib and EGF-816 are third-generation EGFR–
TKIs that covalently bind to EGFR and are effective against the
T790M-mutated EGFR, the most common mechanism of
acquired resistance to ﬁrst-generation EGFR–TKIs. EGF-816 is
not yet accessible except for clinical trials. All classes of EGFR–
TKIs are active against the EGFR-activating mutation alone.
Therefore, we evaluated the sensitivity of the EGFR–
TKI-resistant mutations introduced into Ba/F3 cells (T790M/
activating mutation or C797S/T790M/activating mutation
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(triple-mutation)) to the clinically relevant EGFR–TKIs geﬁtinib,
afatinib, osimertinib and EGF-816.
The CellTiter-Glo assay showed that geﬁtinib and afatinib were
effective against the EGFR-activating mutation, as previously
described, and also potent against the double mutation with
C797S, which is the covalent binding site of the second- and
third-generation EGFR–TKIs (Supplementary Fig. 1a–d). How-
ever, they are no longer effective against the T790M gatekeeper
mutation, the most relevant mechanism of resistance to the ﬁrst-
generation EGFR–TKIs. Osimertinib and EGF-816 showed
efﬁcacy not only against the EGFR-activating mutation alone
but also against the double mutation with T790M in vitro
(Supplementary Fig. 1e,f). Although the resistance due to the
T790M mutation has been shown to be overcome by the third-
generation EGFR–TKIs, they lost their inhibitory activity when
the C797S mutation occurred concurrent with the T790M in cis.
The Ba/F3 cells expressing the triple-mutant EGFR were entirely
resistant to all generations of EGFR–TKIs with similar IC50 values
as in the parental Ba/F3 cells (Supplementary Fig. 1g–i and
Table 1a,b). We examined the sensitivity of PC9 cells (parental;
expressing del19 alone) and resistant PC9 cells (T790M; double
mutation del19 with T790M, triple-mutant; generated by
introducing C797S/T790M/del19 (triple-del19) mutant EGFR)
to the EGFR–TKIs to conﬁrm the characteristics demonstrated in
Ba/F3 cells. The CellTiter-Glo assay revealed similar results in the
PC9 triple-mutant cells that were also refractory to all EGFR–
TKIs as seen in Ba/F3 cells (Supplementary Fig. 2a–c and
Table 1c). Interestingly, PC9 triple-mutant cells showed no
sensitivity to the combination therapy of geﬁtinib and osimertinib
that was shown to overcome the acquired osimertinib resistance
mediated by C797S and T790M mutations in trans
(Supplementary Fig. 2d). These results suggest that no clinically
beneﬁcial drug is available for the treatment of the triple-mutant
EGFR.
Brigatinib overcomes the resistance of EGFR-triple-mutant. To
investigate the candidates who could overcome the triple-mutant
EGFR, we performed a focused drug screening to examine their
efﬁcacy against each type of EGFR-del19 mutation in Ba/F3 cells
using the CellTiter-Glo assay. The 30 drugs used in the focused
drug screening comprised not only EGFR–TKIs but also kinase
inhibitors targeting other tyrosine kinases or serine/threonine
kinases that are now available clinically or are being evaluated in
clinical trials, referring to the report by Duong-Ly et al.44 that
showed the potential to repurpose inhibitors against disease-
associated or drug-resistant mutant kinases. Among TKIs, only
brigatinib and ponatinib were expected to have inhibitory activity
against EGFR-triple-del19 with B50% growth inhibition at
100 nM (Fig. 1a). However, the potency of ponatinib against
triple-del19 assessed by the CellTiter-Glo assay was disappointing
with almost the same IC50 value as that in the parental Ba/F3
cells (Supplementary Fig. 3). We then evaluated the efﬁcacy
of brigatinib in T790M/del19 and triple-del19-mutated
Table 1 | IC50 values (nM) for the mutant EGFR-expressing Ba/F3 cells, PC9 cells or MGH121 cells.
(a) IC50 values of Ba/F3 cells expressing EGFR-del19 series to EGFR–TKIs
Ba/F3-EGFR- Geﬁtinib Afatinib Osimertinib EGF-816
Del19 5.9 o0.3 1.7 2.9
T790M/del19 5,603 78.2 6.7 18.5
C797S/del19 2.7 2.1 513.4 1,241
C797S/T790M/del19 2,922 392.7 740.5 1,408
Parent(þ IL-3) 410,000 381.3 752.4 –
(b) IC50 values of Ba/F3 cells expressing EGFR-L858R series to EGFR–TKIs
Ba/F3-EGFR- Geﬁtinib Afatinib Osimertinib EGF-816
L858R 10.4 o0.3 3 7.7
T790M/L858R 5,922 39.2 5.8 15.5
C797S/L858R 15.5 7.7 1,115 1,659
C797S/T790M/L858R 410,000 804.2 1,171 2,278
(c) IC50 values of PC9 cells to EGFR–TKIs
Geﬁtinib Afatinib Osimertinib
PC9 parent 16.38 0.638 7.463
PC9 T790M 14,684 61.94 11.31
PC9 triple 410,000 1,130 3,461
(d) IC50 values of PC9 cells to ALK–TKIs
Brigatinib AP26113-analog AZD3463
PC9 parent 132.8 46.18 253
PC9 T790M 243.8 89.28 378.3
PC9 triple 599.2 194.7 622.4
(e) IC50 values of MGH121 cells to EGFR–TKIs
Geﬁtinib Osimertinib Brigatinib
MGH121-pt 3,228 2.58 155.3
MGH121-res2 410,000 7,155 592.1
EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors;
(a–b) IC50 values for the Ba/F3 cells expressing EGFR-activating mutations with or without resistant mutations, the del19 series (a) and the L858R series (b), respectively, treated with the indicated
EGFR–TKIs. (c–d) IC50 values for PC9 cells (parental, T790M or C797S/T790M/del19-induced) treated with the indicated EGFR–TKIs (c) or ALK–TKIs (d). (e) IC50 values for the MGH121 parental and
res-2 cells treated with the indicated TKIs.
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EGFR-expressing Ba/F3 cells using the CellTiter-Glo assay
compared with other clinically available EGFR–TKIs. The assay
demonstrated that only brigatinib inhibited the growth of Ba/F3
cells expressing the triple-del19 mutation with a low IC50
(o100 nM; Fig. 1b). The addition of IL-3 as an original
survival signalling pathway activator counteracted this
inhibitory effect of brigatinib. The potency of brigatinib in
triple-del19 was conﬁrmed by western blotting that showed
decreased phosphorylation of EGFR and its downstream
signalling pathway in a dose-dependent manner in contrast to
the lack of inhibition of EGFR phosphorylation by afatinib and
osimertinib (Fig. 1c). Although brigatinib showed acceptable
inhibitory activity in cell growth inhibition and EGFR signal
pathway also in Ba/F3 cells expressing EGFR-del19 alone,
T790M/del19 or C797S/del19, its efﬁcacy was only superior to
that of osimertinib against C797S/del19 (Supplementary Fig. 4).
The cell growth inhibition assay and western blotting using same
setting of EGFR–TKIs in Ba/F3 cells expressing mutant EGFR
activated by L858R (L858R alone, T790M/L858R, C797S/L858R
and C797S/T790M/L858R (triple-L858R)) showed that brigatinib
was also effective in EGFR-L858R series but was less potent than
in del19, with similar pattern of efﬁcacy observed in Ba/F3 cells
expressing corresponding mutation types of EGFR activated by
del19 (Supplementary Fig. 5).
To evaluate whether or not brigatinib acts on EGFR through
ATP competition, and to compare its activity between triple-
mutant EGFR and wild-type EGFR, an in vitro kinase assay was
performed using an ADP-Glo kit. The kinase activity inhibition













































































































































































































Figure 1 | Identiﬁcation of brigatinib as an EGFR-C797S/T790M/activating-mutation (triple-mutant EGFR) inhibitor. (a) The results of screening the
growth-inhibitory activity of 30 drugs in Ba/F3 cells expressing four types of EGFR-del19 with or without T790M or C797S mutations are shown in a heat
map. Ba/F3 cells expressing each EGFR mutant were treated with 100 nM of the indicated inhibitors. After 72 h of drug treatment, the cell viability was
measured using the CellTiter-Glo assay. Relative cell viability was calculated from each value divided by the DMSO control. Among the inhibitors, only
brigatinib and ponatinib were sufﬁciently efﬁcacious against the triple-mutant EGFR. AZD3463 acted as a weak inhibitor to the triple mutation. (b) Growth
inhibition assessed by the CellTiter-Glo assay of EGFR-C797S/T790M/del19 (triple-del19)-mutated Ba/F3 cells treated with geﬁtinib, osimertinib and
brigatinib.; N¼ 3. Results are expressed as mean±s.d. IC50 values were calculated using growth inhibition assay. (c) Phosphorylation of EGFR and
downstream signals were signiﬁcantly inhibited by brigatinib in Ba/F3 cells expressing triple-del19 even though afatinib and osimertinib did not suppress at
all the EGFR signalling of triple-del19.
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curves demonstrated by this assay shifted with the ATP
concentrations in both the triple-mutant and wild-type EGFR,
indicating that brigatinib competitively affected the ATP-binding
site of the EGFR kinase domain (Fig. 2a,b). The higher potency of
brigatinib to triple-mutant EGFR was conﬁrmed by the IC50 value
calculated for 10 mM ATP, which wasB10 times lower for triple-
L858R than for the wild type (Fig. 2c). Furthermore, brigatinib
showed less inhibitory activity to the cell lines without EGFR
mutation than afatinib and osimertinib when compared with the
IC50 values of each drugs, especially in the wild-type EGFR-
ampliﬁed A431 cells. In the KRAS-mutated A549 or H460 cells,
all these inhibitors had high IC50 values. From these results,
brigatinib was expected to have a preferable toxicity proﬁle
related to wild-type EGFR inhibition compared with afatinib or
even osimertinib (Fig. 2d and Supplementary Fig. 6a–c).
The activity of other ALK inhibitors with similar structure. As
brigatinib was developed as a next-generation anaplastic
lymphoma kinase (ALK)–TKI45,46, we then investigated several
ALK–TKIs with similar structures—AP26113-analog, AZD3463,
TAE684, ceritinib and ASP3026 (Fig. 3a). Cell growth inhibition
experiments using the CellTiter-Glo assay demonstrated that
brigatinib and AP26113-analog had similar potency against the
triple mutation with IC50 values ofo100 nM, whereas AZD3463
was moderately active followed by TAE684 and two other drugs
that showed no activity (Fig. 3b,c and Supplementary Fig. 7a–d).
The differences in efﬁcacy between these drugs in cell growth
inhibition were reproduced in western blotting experiments
showing that brigatinib and AP26113-analog more effectively
suppressed phosphorylation of EGFR and its downstream
signalling pathway in cells expressing all types of EGFR
mutations (Fig. 3d,e and Supplementary Fig. 7e,f). These
experiments also suggested that L858R tends to be less sensitive
to inhibitors than del19 (Supplementary Figs 8,9). Comparison of
the chemical structures of the ALK–TKIs suggested that some
functional groups have a key role in increasing the binding
afﬁnity to the triple-mutant EGFR. First, the phosphine oxide
group in brigatinib and AP26113-analog, but not the
isopropylsulfonyl group in TAE684, ceritinib and ASP3026,
might contribute to their greater activity against the triple-mutant
EGFR. Second, the presence of an isopropoxy group in ceritinib
but no methoxy group in other ALK–TKIs and the absence of
chloride in ASP3026 might work as negative factors (Fig. 3).
In silico simulation of brigatinib binds to triple-mutant EGFR.
We performed the in silico docking simulation and molecular
dynamic simulation to assess the binding compatibility between
brigatinib and the triple-L858R mutant EGFR and to clarify
whether the efﬁcacy of brigatinib against the triple-mutant EGFR
depends on targeting of the ATP-binding site (Supplementary
Fig. 10). In our simulations, brigatinib ﬁtted into the ATP-
binding pocket of EGFR-triple-L858R without sterically crowding
T790M or C797S (Fig. 4a,b), forming two hydrogen bonds with
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Figure 2 | Brigatinib inhibited EGFR through ATP competition and was less potent to wild-type EGFR or non-EGFR-mutated cells. (a–c) The evaluation
of the inhibitory activity of brigatinib in the in vitro kinase assay using the ADP-Glo assay kit showed a dose-dependent decrease in EGFR activity with
brigatinib according to the increase of ATP concentration in either (a) EGFR-C797S/T790M/L858R or (b) wild type; N¼ 3. Results are expressed as
mean±s.d. (c) IC50 value calculated at an ATP concentration of 10mM suggested the better afﬁnity of brigatinib to EGFR-C797S/T790M/L858R than to
wild-type EGFR. (d) IC50 values calculated from the cell viability assay of non-EGFR-mutated cell lines, A431, A549 and H460, assessed using CellTiter-Glo
assay kit are shown with a dot plot.
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binding conformation in the docked complex model was quite
similar to that in the crystal structure of EML4-ALK bound to
TAE684 (PDB-ID: 2XB7). This ﬁnding is considered to be rea-
sonable because of high similarities between both protein and
chemical structures of the two inhibitors. Although these struc-
tural analyses suggest that these two inhibitors were presumed to
bind to EGFR with similar orientations, activity to triple-mutant
EGFR signiﬁcantly differed from each other in cell growth inhi-
bition or western blotting (Fig. 3c,e). For explanation of the
difference in the inhibitory activities, the docking model hinted
advantageous substructures in brigatinib for EGFR binding. In
the docked EGFR–brigatinib model, the phosphine oxide group
fully occupies the triphosphate-binding space in the ATP-binding
site (Fig. 4d), concomitantly with meaningful gains of the elec-
trostatic or van der Waals interaction energy for all atoms in this
group (Fig. 4e,f), suggesting speciﬁc interaction with EGFR. In the
case of TAE684, its substitution with the isopropylsulfonyl group
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Figure 3 | Efﬁcacy of brigatinib and similarly structured drugs in the EGFR-mutated Ba/F3 cells and their chemical structures. (a) Chemical structures
of six ALK–TKIs were very similar. (b,c) IC50 values in Ba/F3 cells expressing four mutation types of EGFR-del19 were obtained by treatment with brigatinib,
AP26113-analog, AZD3463, TAE684, ceritinib and ASP3026 for 72 h. Those of C797S/T790M/del19 were shown by bar graph (b) and those of all
mutation types were demonstrated by a table (c). The CellTiter-Glo assay was used to measure cell viability. (d,e) Ba/F3 cells expressing T790M/del19
(d) or C797S/T790M/del19 (e) were treated with the indicated concentrations of brigatinib, AP26113 analog, TAE684, ceritinib or ASP3026 for 6 h.
Phosphorylation of EGFR and its downstream signals were evaluated by western blotting with the indicated antibodies.
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the superiority of brigatinib to TAE684 for triple mutation shown
in this study. This interaction map between brigatinib and triple-
mutant EGFR represents that the components B and E con-
tributed less to the afﬁnity than other compartments and were
suitable for structural modiﬁcation (Fig. 4f).
Effectiveness of brigatinib in lung cancer cell lines. We then
evaluated the effectiveness of brigatinib and other TKIs against
triple-del19-positive lung cancer cell lines. CellTiter-Glo assays
demonstrated that the growth of PC9 parental cells (del19 alone)
and double-mutant (T790M/del19) or triple-mutant (C797S/
T790M/del19) cells was inhibited by geﬁtinib, osimertinib and
brigatinib with a pattern similar to that observed in Ba/F3 cells
expressing the corresponding mutation type (Fig. 5a–c and
Table 1d). In western blotting, only brigatinib inhibited EGFR
phosphorylation and its downstream signalling in PC9 triple-
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Figure 4 | Structure model of EGFR–brigatinib interactions. (a,b) The brigatinib-binding mode for the EGFR-C797S/T790M/L858R mutant (EGFR-triple-
L858R). The mean structure of the EGFR–brigatinib complex, generated by molecular dynamic simulations for 10 docking poses, is shown. EGFR was
depicted by a surface model (T790M, blue; C797S, purple; others, grey), and brigatinib was depicted by sticks (C, green; N, blue; O, red; P, orange; and H,
hydrogen). In the structure model, brigatinib ﬁts into the ATP-binding pocket without a sterical crush to T790M and C797S demonstrated by overview
(a) and zoom-in of ATP-binding pocket (b). (c) Hydrogen bonds between the triple-mutant EGFR and brigatinib. The protein backbone and M793 of EGFR-
triple-L858R were depicted by a grey backbone tube and sticks (C, grey; N, blue; O, red and H, hydrogen), respectively. Hydrogen bonds were shown by
dashed yellow lines. (d) Comparison of the inhibitor-binding mode between the EGFR–brigatinib and ALK–TAE684 complexes. TAE684 was depicted by
thick sticks (C, magenta; N, blue; O, red; S, yellow; and H, hydrogen) after the crystal structure of EML4-ALK in complex with TAE684 (PDB-ID: 2XB7) was
superimposed to the modelling structure of EGFR (a grey surface model) in complex with brigatinib (a space-ﬁlling model with thin sticks). (e) Substructure
and atom IDs in the energy plot were assigned to the chemical structure of brigatinib. (f) The mean interaction energy between the EGFR-triple-L858R and
a brigatinib atom was calculated using molecular dynamic trajectories for 10 docking poses. Negative and positive values indicate favourable and repulsive
interactions, respectively.
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was yielded by afatinib and osimertinib in contrast with obser-
vations of diminished EGFR signalling in PC9 parent and T790M
cells (Fig. 5f and Supplementary Fig. 11a,b). AZD3463 showed
mild activity in these PC9 cells assessed using western blotting
(Supplementary Fig. 11c). Moreover, these three EGFR–TKIs
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Figure 5 | Inhibition of cell growth and downstream signal pathway in lung cancer cell lines by brigatinib. (a–e) PC9 (del19) (a), PC9-T790M (T790M/
del19) (b), PC9-triple mutant (C797S/T790M/del19) (c), MGH121 parent (T790M/del19) (d) and MGH121 resistant-2 (C797S/T790M/del19) (e) cells
were treated with serially diluted geﬁtinib, osimertinib and brigatinib for 72 h. Cell viability was measured using the CellTiter-Glo assay.; N¼ 3. Results are
expressed as mean±s.d. (f) Western blotting of PC9 triple mutant (C797S/T790M/del19) cells indicated that brigatinib and AP26113 analog, but not
afatinib or osimertinib, suppressed phosphorylation of EGFR and its downstream signalling. (g) Similar results were obtained in MGH121 resistant-2.
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cells derived from an erlotinib-failure patient harbouring T790M/
del19 and in MGH121-resistant-2 cells expressing triple-del19
established as WZ-4002–resistant MGH121 cells in vitro43
(Fig. 5d,e,g, and Table 1e).
Efﬁcacy of brigatinib to triple-mutant EGFR in vivo. To con-
ﬁrm the superior activity of brigatinib against the triple-mutant
EGFR, we performed in vivo experiments by administering bri-
gatinib or osimertinib to nude mice into which EGFR-triple-del19
expressing PC9 lung cancer (PC9-triple mutant) cells had been
subcutaneously injected. As a result, the mice treated with bri-
gatinib showed signiﬁcant inhibition of the growth of PC9-triple
mutant cells compared with vehicle controls and osimertinib-
treated group without explicit toxicity (Supplementary
Fig. 12a,b). Phosphorylation of EGFR and its downstream sig-
nalling were actually inhibited by brigatinib in tumour samples
obtained from mice (Supplementary Fig. 12c). This in vivo efﬁ-
cacy was conﬁrmed in similar experiments using Ba/F3 cells
expressing EGFR-triple-del19 instead of PC9 cells. Of note, osi-
mertinib (50mg kg 1) and brigatinib (75mg kg 1) both suc-
cessfully suppressed the growth of T790M/del19-expressing PC9
cells (Supplementary Fig. 13). These results suggested that bri-
gatinib took advantage of triple mutation regardless of cell type
and will be a promising candidate to overcome the acquired
resistance of third-generation EGFR–TKIs. To attain better
therapeutic effect and tumour shrinkage, it would be important to
develop more potent inhibitors than brigatinib based on our
structural analysis in future studies.
The anti-EGFR antibody enhances the efﬁcacy of brigatinib.
Referring to a previous report that stated that afatinibþ cetuximab
combination was effective for acquired resistance of ﬁrst-genera-
tion EGFR–TKI in preclinical models and patients25,47, we
evaluated the combination of brigatinib and cetuximab or
panitumumab against the triple-mutant EGFR. The cell viability
assay using Cell-Titer Glo kit demonstrated that cetuximab
enhanced the efﬁcacy of brigatinib or AP26113-analog against
triple-del19 Ba/F3 cells with approximately three-fold decrease of
IC50, whereas no synergistic beneﬁt was obtained in osimertinib
(Fig. 6a). The potentiated inhibition of downstream pathway by
combination of brigatinib with cetuximab was observed using
western blotting (Fig. 6b). These effects were reproduced among
triple-mutation lung cancer cell lines both in cell viability assay and
western blotting analysis (Fig. 6c–f). The other anti-EGFR
antibody, panitumumab in combination with brigatinib,
indicated similar growth inhibition (Supplementary Fig. 14a–c).
To further understand the beneﬁt of combination with anti-
EGFR antibody, we evaluated the cell surface expression of EGFR
in PC9 triple-mutant cells after treatment with cetuximab,
brigatinib and brigatinibþ cetuximab in combination for 0, 6, 24
and 48h. EGFR expression analysis by ﬂow cytometry of the
treated cells demonstrated a signiﬁcant decrease over time in the
cell surface EGFR level with brigatinibþ cetuximab and a
moderate decrease with cetuximab alone, but it demonstrated no
reduction with brigatinib alone (Fig. 7a). Western blot analysis of
the corresponding treated cells showed that the decrease of total
cellular EGFR achieved with cetuximab was potentiated when the
cells were treated with brigatinib and cetuximab in combination
and that the inhibition of phosphorylation of EGFR along with
downstream signalling was also enhanced by this combination
(Fig. 7b). In addition, the same experiments conﬁrmed the
suppression of total and cell surface EGFR expression using
triple-del19-mutated EGFR-expressing MGH121-res2 cells
(Fig. 7c,d). These results suggest that synergy of brigatinib and
cetuximab was induced through the degeneration of EGFR on the
surface caused by cetuximab resulting in intensiﬁcation of the
efﬁcacy of brigatinib. We then performed in vivo experiments of
PC9 triple-mutant xenograft cells as described above comparing
with vehicle control, brigatinib alone, osimertinib alone, cetuximab
alone, combination of osimertinib and cetuximab and combination
of brigatinib and cetuximab. The combination of brigatinib and
cetuximab demonstrated signiﬁcant suppression of tumour growth
without toxicity and achieved prolongation of survival periods
compared with other treatment groups, especially osimertinib-
treated group without any superiority to control group (Fig. 8a–c).
We conﬁrmed that its efﬁcacy depended on the inhibition of
phosphorylation of EGFR and the decreased expression of EGFR
itself in western blotting of tumour samples obtained from each
treatment group (Fig. 8d). Panitumumab, another anti-EGFR
antibody used for treating patients with colorectal cancer, showed a
comparable synergistic effect as cetuximab in an in vivo experiment
(Fig. 8e–g). Western blotting of resected xenografts showed that the
synergy was also induced through combination with panitumu-
mab, suggesting the importance of the concurrent anti-EGFR
antibody regardless of its mode of action (Fig. 8h). Another EGFR-
triple-mutated lung cancer xenograft model using MGH121-
res2 cells showed not only a growth inhibition effect with
brigatinib but also a signiﬁcant tumour shrinkage without toxicity
with a combination treatment of cetuximab and brigatinib
(Fig. 9a,b).
Discussion
In this study, we demonstrated the efﬁcacy of brigatinib against
triple-mutant EGFR-positive cells that acquired resistance even to
third-generation EGFR–TKIs. Engineered Ba/F3 cells overexpres-
sing triple-mutant EGFR were shown to be sensitive to brigatinib
not only in vitro but also in vivo, as were the lung cancer cell lines
with the triple-mutation in vitro (Figs 1 and 5). Brigatinib also
demonstrated growth inhibition activity in PC9 triple-mutant
xenograft model and in combination with anti-EGFR antibody to
potentiate the efﬁcacy both in vitro and in vivo as shown in ﬁrst-
generation EGFR–TKI-resistant patients (Figs 8 and 9 and
Supplementary Fig. 12). Discovery of a promising drug that is
effective against the triple mutation should be meaningful
considering that the approval of osimertinib, the third-generation
EGFR–TKI, in the United States and other countries may lead to
a rapid increase in cases of acquired resistance due to the triple-
mutant EGFR in the clinical setting.
As brigatinib is now under clinical development as an
ALK–TKI48, we also investigated the efﬁcacy of similarly
structured ALK–TKIs against the triple-mutant EGFR.
However, no other drugs exceeded brigatinib and its analog
(Figs 3 and 5 and Supplementary Figs 7–9, 11). We had doubts
about the disparity in their activity even if it is true that brigatinib
was originally developed as a dual inhibitor of EGFR and ALK.
The structure–activity relationship and computer simulation
suggested that the chloro, phosphine oxide group and methoxy
group of brigatinib worked as key elements that contribute to its
superior efﬁcacy for triple-mutant EGFR (Fig. 3a–c). Also, these
groups meaningfully gained the electrostatic or van der Waals
intermolecular interaction energy in molecular simulation
(Fig. 4e,f), supporting the speculation from the structure–
activity relationship. The binding pose of brigatinib also
revealed that sufﬁcient space appears to be available for
substitutions on the piperidine ring and a phenyl ring
connected to the phosphine oxide group, concomitantly with
smaller contributions of the two substructures to the binding
stability (Fig. 4e,f). These two functional groups (mentioned as
parts B and E in Fig. 4e,f) may be suitable to be partially modiﬁed
to achieve better binding afﬁnity because of their lesser
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involvement in the predicted binding mode. These implications
provide the opportunity to develop more potent new drugs by
investigating derivatives of brigatinib in the future.
This study had several limitations. First, brigatinib did not
demonstrate satisfactory efﬁcacy in patients with EGFR-mutated
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Figure 6 | Brigatinib combined with cetuximab synergistically suppressed the growth of EGFR-C797S/T790M/del19-expressing cells in vitro. (a) The
cell growth inhibition of Ba/F3 cells expressing EGFR-C797S/T790M/del19 (EGFR-triple-del19) treated with brigatinib, AP26113-analog, AZD3463 and
osimertinib at indicated concentrations combined with or without cetuximab (10mgml 1) for 72 h assessed by CellTiter-Glo assay. (b) Inhibition of EGFR
signal pathway in BaF3 EGFR-triple-del19 cells treated with brigatinibþ cetuximab (10mgml 1) for 6 h was evaluated using western blotting. (c,d) The cell
growth inhibition of PC9 triple-mutant cells (c) and MGH121-res2 cells (d) treated with brigatinib and osimertinib at indicated concentrations combined
with or without cetuximab (10 mgml 1) for 72 h assessed by CellTiter-Glo assay. (e,f) Inhibition of EGFR signal pathway in PC9 triple-mutant cells (e) and
MGH121-res2 cells (f) treated with brigatinibþ cetuximab (10 mgml 1) for 6 h was evaluated using western blotting.; Results in a,c,e are expressed as
mean±s.d. (N¼ 3). The signiﬁcance of difference between indicated groups are calculated by Student’s t-test (NS; not signiﬁcant, *Po0.05, **Po0.01).
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cases achieved partial response48. However, the plasma
concentrations of brigatinib at 180mg per day in a steady state
reported previously (1,694.3 nM (ref. 48) and 1,447 nM (ref. 49))
were higher than the IC50 values for triple-mutant EGFR
presented in our study (Figs. 1b,3c and Table 1d,e). We expect
that a combination of brigatinib and anti-EGFR antibody would
improve sensitivity to the triple-mutant EGFR, resulting in better
efﬁcacy as shown in our study of the long-term tumour stability
in PC9 triple-mutant xenografts and signiﬁcant tumour shrinkage
in MGH121-res2 xenografts; this implies that long-term ‘stable
disease’ or ‘partial response’ was achieved with the combination
therapy, whereas only the inhibition of tumour growth was
attained with brigatinib monotherapy. Second, there is limited
evidence that brigatinib directly affects the ATP-binding site of
the triple-mutant EGFR because of the absence of a co-crystal
structure, although our in vitro kinase assay results suggest that
brigatinib inhibits triple-mutant EGFR in an ATP-competitive
manner, and our computer simulation demonstrated its
ba
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Figure 7 | Brigatinib combined with cetuximab enhanced internalization and reduced EGFR expression. (a) FACS analysis using a PE-conjugated EGFR
antibody of PC9 triple-mutant cells treated with brigatinib, cetuximab, brigatinibþ cetuximab for 0, 6, 24 and 48 h demonstrated a time-dependent marked
decrease in surface EGFR after treatment with brigatinibþ cetuximab over a period of up to 48 h, and a moderate decrease with cetuximab alone.
(b) Western blotting assessment of the cells corresponding to the treatments in a. (c,d) FACS analysis and western blotting performed with MGH121-res2
cells using the same method as with the PC9 triple-mutant cells in a,b.
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Figure 8 | Brigatinib combined with cetuximab or panitumumab synergistically suppressed the growth of EGFR-C797S/T790M/del19-expressing cells
in vivo. (a,b) PC9 cells expressing EGFR-C797S/T790M/del19 were subcutaneously implanted into Balb-c nu/nu mice. When the average tumour volume
reached B200mm3, the mice were randomized into vehicle control or treatment groups (50mg kg 1 of osimertinib, 75mg kg 1 of brigatinib, 1mg per
mouse of cetuximab three times a week or 75mg kg 1 of brigatinib combined with cetuximab administered as previously described) and treated once daily
by oral gavage for the indicated period. Tumour volume (V) was calculated as 0.5 lengthwidth2, and body weights (B.W.) of mice were measured twice
weekly.; N¼ 6. Results are expressed as mean±s.d. The signiﬁcance of difference between the mean tumour volume of control and of brigatinib on day 7,
between brigatinib and brigatinibþ cetuximab on day 23, respectively, are calculated by Mann–Whitney U test (**Po0.01). (c) Survival periods of mice in
each treatment arm were demonstrated using the Kaplan–Meier curve. (d) Phosphorylation of EGFR and its downstream signalling in two tumour samples
obtained from each group were evaluated using western blotting. (e,f) In vivo experiment of PC9 triple-mutant cells following a similar protocol as in
Fig. 8a–b, using panitumumab 0.5mg per mouse two times a week administered peritoneally instead of cetuximab.; N¼6. Results are expressed as
mean±s.d. The signiﬁcance of difference between the mean tumour volume of control and of brigatinib on day 16, between brigatinib and
brigatinibþ panitumumab on day 23, respectively, are calculated by Mann–Whitney U test (**Po0.01). (g) A Kaplan–Meier curve of the survival of the
mice in each treatment arm. (h) Phosphorylation of EGFR and its downstream signalling in two tumour samples obtained from xenografts of PC9-triple
mutant cells treated for 8 days with the indicated drugs (brigatinib: 75mg kg 1 daily, administered orally; panitumumab: 0.5mg per mouse two times a
week, administered peritoneally) were assessed by western blotting with the indicated antibodies.
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compatible interaction with the triple-mutant EGFR. Third, we
have not yet experienced a sufﬁcient number of cases of
osimertinib resistance to estimate the true number of the triple-
mutant EGFR. Up to the present, the prevalence of the triple
mutation was estimated to be 2–4% among patients with lung
cancer according to the frequency of 22% among osimertinib-
resistant cases reported in WCLC2015 (ref. 50), and the C797S
population would be equal to that of ALK-rearranged lung cancer
patients with a similar clinical magnitude. In addition, in our
N-ethyl-N-nitrosurea mutagenesis drug screen, all clones
resistant to osimertinib mediated only the C797S mutation
(unpublished data). Unless the triple-mutant EGFR occurs less
frequently than is currently expected (B20%), beating the triple-
mutant EGFR is a worthy challenge as it is highly refractory to
available drugs, although we can hope to overcome resistance due
to other mechanisms such as T790M loss or bypass pathway
activation using existing treatment modalities, for example,
turning back to ﬁrst-generation EGFR–TKIs or combination
therapy.
In conclusion, we found brigatinib to be potent against the
triple-mutant EGFR in a focused drug-screening protocol and
conﬁrmed its activity in in vivo and in vitro assays. The activity
depended on ATP-competitive manner with less affection to
wild-type EGFR. The combination therapy with anti-EGFR
antibody showed more preferable activity than monotherapy
in vitro and in vivo without toxicity. The structure–activity
relationship demonstrated that the efﬁcacy of brigatinib exceeded
that of its analogs, identifying several key basic structure and
functional groups, such as the phosphine oxide group predicted
from the computer simulation. The simulation indicated not only
the conformation of brigatinib binding to the triple-mutant EGFR
ATP-binding pocket in a compatible manner but also the
potential for developing a more potent inhibitor by partial
substitution in future direction. While the potency of brigatinib
monotherapy does not seem to be completely satisfactory, the
combination with anti-EGFR antibody strikingly reduced IC50
against triple-mutant EGFR by inducing the degradation of
surface and total EGFR expression, leading to tumour shrinkage
of the triple-mutant EGFR-harbouring cells and signiﬁcant
prolongation of the survival of xenograft-bearing mice. Given
that the development of brigatinib is now in the late phase of
clinical trials and anti-EGFR antibodies are now broadly used
clinically for several cancers other than lung cancer, the ﬁndings
of this study should help to overcome the acquired resistance to
third-generation EGFR–TKIs.
Methods
Kinase inhibitors and other drugs. The drugs used in the experiments and the
companies from which they were purchased are shown in Supplementary Table 1.
Reagents and cell culture. MGH121 (EGFR-T790M/del19 derived from a lung
cancer patient), MGH121-resistant-2 (EGFR-C797S/T790M/del19), PC9 parent
(ampliﬁed EGFR-del19), PC9 T790M (ampliﬁed EGFR-T790M/del19) and PC9
triple-mutant (ampliﬁed EGFR-C797S/T790M/del19) cells were cultured in RPMI
with 10% serum. These cells were kindly provided by Drs. Niederst and Engelman.
Ba/F3 cells harbouring EGFR mutations were cultured in low-glucose Dulbecco’s
minimal essential medium (DMEM) with 10% fetal bovine serum (FBS). The
MGH121 resistant-2 cells were established from MGH121 by treating with 1 mM
WZ-4002, and the PC9 T790M cells were obtained from PC9 parental cells by
treating with 1 mM geﬁtinib as de novo persistent resistant clone43. The PC9 triple
mutant cells were generated by lentivirus infection of EGFR-triple-del19 from the
PC9 parental cells. All cells were routinely tested and veriﬁed to be free of
mycoplasma contamination.
Generating lentivirus and stable expression in Ba/F3 cells. The full-length
wild-type EGFR was synthesized from cDNA obtained from A549 cells. The EGFR-
activating mutation, del19 or L858R, was obtained from the cDNA of EGFR-exon
19 deletion (del19)-harbouring HCC827 cells or L858R-harbouring lung cancer
specimens, respectively. Each EGFR was ampliﬁed using polymerase chain reaction
and then cloned into a pENTR vector. The T790M and/or C797S mutants were
generated by QuikChange site-directed mutagenesis using the following primers:
T790M F- 50-CCGTGCAGCTCATCATCCAGCTCATGCCCTTC-30 , and T790M
R- 50-GAAGGGCATGAGCTGCATGATGAGCTGCACGG-30 , C797S F- 50-CAT
GCCCTTCGGCTCCCTCCTGGAGCTA-30 , and C797S R – 50-TAGTCCAGGAG
GGAGCCGAAGGGCATG-30.
The resulting pENTR-EGFR mutation constructs were sequenced and used as a
template to make the pLenti6.3 lentiviral vector using LR clonase II. The lentivirus
was made by transfecting the pLenti6.3 constructs along with helper plasmids
(ViraPower) in 293FT cells. Virus production, collection and infection were
completed following the manufacturer’s protocol. The Ba/F3 cells were selected by
culturing for 1 week with 7 mM blasticidin in DMEM with interleukin-3 (IL-3)-
supplemented 10% FBS and then in DMEM without IL-3 to obtain the EGFR
signalling-addicted cells.
Cell viability assays. Three-day cell viability assays were carried out by plating
2,000, 1,500 and 2,000 cells per well of Ba/F3, PC9 or MGH121, respectively, into
black transparent-bottom 96-well plates. On the same day for Ba/F3 cells and the
following day for PC9 and MGH121 cells, the cells were treated with each TKI
across a 10-dose range from 0.3 nmol l 1 to 10 mmol l 1. After 72 h of drug
treatment, cell viability was measured using the CellTiter-Glo assay (Promega).
Drug sensitivity screening. Ba/F3 cells of EGFR-del19, -T790M/del19, -C797S/
del19 and -C797S/T790M/del19 were plated with 2,000 cells per well into black
96-well plates and treated for 3 days with a panel of 30 inhibitors including
dimethylsulfoxide (DMSO) controls prepared in-house. After the incubation, cell
viability was measured using CellTiter-Glo assay. The relative cell viability was
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Figure 9 | Brigatinib combined with cetuximab synergistically suppressed
the growth of EGFR-C797S/T790M/del19-expressing lung cancer cells
in vivo. (a,b) MGH121-res2 expressing EGFR-C797S/T790M/del19 were
subcutaneously implanted into SCID-beige mice. When the average tumour
volume reachedB200mm3, the mice were randomized into vehicle control
and treatment groups (50mg kg 1 of osimertinib (po), 75mg kg 1 of
brigatinib (po), 1mg per mouse of cetuximab two times a week and
75mg kg 1 of brigatinib combined with cetuximab administered as
previously described, respectively) and treated for the indicated period.
Tumour volume (V) was calculated as 0.5 lengthwidth2, and the body
weights (B.W.) of the mice were measured twice weekly. N¼ 6. Results are
expressed as mean±s.d. The signiﬁcance in difference between the mean
tumour volume of control and of osimertinib, brigatinib and cetuximab,
between cetuximab and brigatinibþ cetuximab, respectively, on day 42
are calculated by Mann–Whitney U test (NS: not signiﬁcant, *Po0.05,
**Po0.01).
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repeated three times independently, and the average relative cell viability was
calculated and shown as a heat map (Original data are available in Supplementary
Data 1).
Antibodies and western blotting. Tumour tissues or cells grown under the
speciﬁed conditions were washed with cold PBS before addition of the SDS lysis
buffer (100mM Tris, 1% SDS, 10% glycerol). Lysates were transferred to micro-
tubes, boiled for 5min at 100 C and then vortexed. Protein quantiﬁcation was
performed using the BCA Protein Assay Reagent (Pierce) according to the
manufacturer’s protocol. Western blot analyses were conducted after separation
by SDS-PAGE and transferred to polyvinylidene diﬂuoride membranes. After
blocking in 5% BSA with Tris-buffered saline/Tween 20 (TBS-T) or 5% skim
milk/TBS-T, membranes were incubated with phospho-EGFR antibody (Tyr1068;
Abcam, ab5644, 1:1,000), total EGFR (Cell Signaling Technology, #4267, 1:2,000),
phospho-Akt (Ser473; Cell Signaling Technology, #4060, 1:1,000), total Akt (Cell
Signaling Technology, #4691, 1:5,000), phospho-ERK (Thr202/Tyr204; Cell
Signaling Technology, #9101, 1:5,000), total ERK1/2 (Cell Signaling Technology,
#9102, 1:2,000), phospoh-S6 (Ser240/244, Cell Signaling Technology, #5364,
1:10,000), total S6 (Cell Signaling Technology, #2217, 1:2,000) or b-actin (Sigma-
Aldrich, A5228, 1:10,000).
In vitro kinase assay of EGFR protein and inhibitors. The recombinant proteins
of the kinase domain of wild-type EGFR and EGFR-C797S/T790M/L858R were
purchased from Signal Chem. The inhibitors were purchased as described earlier.
The appropriate amount of target proteins calculated on the basis of the ADP-Glo
assay manufacturer’s protocol was incubated in 96-well half area white plates with
serially diluted inhibitor over a 10-dose range from 0.0002 nM to 10 mM for 10min
at room temperature. ATP at concentration of 1, 10, 100 and 1,000 nM was mixed
with 100 mgml 1 substrate and added to a kinase protein–inhibitor mixture, and
then incubated for 60min at room temperature. After the kinase reaction, an equal
volume of ADP-Glo Reagent was added to terminate the kinase reaction, and the
remaining ATP was depleted. The Kinase Detection Reagent was added both to
convert ADP to ATP and to allow the newly synthesized ATP to be measured using
the luciferase/luciferin reaction. The light generated was measured using a
luminometer.
Flow cytometry. To evaluate the level of EGFR, ﬂuorescence-activated cell sorting
(FACS) analysis was performed with PE Mouse Anti-Human EGF receptor (BD
Biosciences, #555997, 100 ml per 1 106 cells) on Cytomics FC500 (BECKMAN
COULTER). The assessed cells were incubated with cetuximab 5 ng for 5min
before the addition of the PE antibody to cancel the cross-activity with cetuximab.
In vivo evaluation of brigatinib and osimertinib. All mouse studies were
conducted through Institutional Animal Care and Use Committee-approved
animal protocols according to the institutional guidelines. PC9-EGFR- C797S/
T790M/del19 (PC9-triple-mutant) cells (6 106) or PC9-EGFR-T790M/del19
(PC9-T790M) cells (6 106) were suspended in 100 ml of 1:2 Matrigel and sub-
cutaneously implanted into Balb-c nu/nu mice (Charles River). Tumour growth
was monitored twice weekly by bilateral caliper measurement, and tumour volume
was calculated as 0.5 lengthwidthwidth (mm3). When the average tumour
volume reachedB200mm3, the mice were randomized into vehicle and treatment
groups using the restricted randomization such that the mean tumour size of each
group was equivalent (control, 50mg kg 1 of osimertinib, or 75mg kg 1 of
brigatinib, respectively). The mice whose implanted tumour size was ranked in the
top 5% and bottom 5% were excluded from randomization to minimize the var-
iation of tumour sizes. The mice were treated once daily by oral gavage for the
indicated period. Relative tumour volume was calculated by dividing by the tumour
volume on day 0. The body weights of the mice were measured twice weekly.
Implanted tumours were resected from the mice on day 15 of drug treatment and
were ﬁxed with formalin. The mice were euthanized when the tumour size
exceeded 700mm3 within several days. The investigators performing tumour
measurements were not blinded to treatment groups. The sample size (minimum
n¼ 6 per treatment group) was selected to ensure satisfactory inter-animal
reproducibility. The Mann–Whitney U test was used for the statistical analysis of
the mice experiments.
Molecular docking simulation. The genetic algorithm-docking programme
GOLD 5.2 was used to perform the molecular docking of brigatinib towards the
C797S/T790M/L858R triple-mutant EGFR. The standard default settings for the
genetic algorithm were used. A protein structure for the docking simulation was set
to the crystal structure of T790M-mutant EGFR in complex with WZ4002 (PDBID:
3IKA), which shares the largest common basic structure with brigatinib. The
structure of a disordered loop (residues Leu989 – Asp1003) and the side chains of
Ser797 and Arg858 were modelled using the Structure Preparation module in
Molecular Operating Environment (MOE, Chemical Computing Group, Montreal,
Canada) version 2013.08 (ref. 51). A compound-binding site in the triple-mutant
EGFR was deﬁned to include all atoms within 10Å of the midpoint of Leu718 Cg
and Gly796 Ca atoms. Brigatinib was docked into the ATP-binding site with
positional restraint on the common basic structure, assuming that this substructure
has a similar binding geometry between brigatinib and WZ4002.
Molecular dynamics simulation of the C797S/T790M/L858R. Ten kinds of
representative binding poses of brigatinib into the C797S/T790M/L858R triple-
mutant EGFR were extracted by the docking simulation and used as initial
structures of the molecular dynamics (MD) simulation. Brigatinib conformation
was optimized, and the electrostatic potential was calculated at the HF/6-31G* level
using the GAMESS programme52, after which the atomic partial charges were
obtained by the RESP approach53. The other parameters for the compound were
determined by the general Amber force ﬁeld54 using the antechamber module of
AMBER Tools 12. The Amber ff99SB-ILDN force ﬁeld was used for protein and
ions55 and TIP3P was used for water molecules56. Water molecules were placed
around the complex model with an encompassing distance of 8Å to form a
83 78 68Å3 periodic box, including roughly 13,000 water molecules. Charge-
neutralizing ions were added to neutralize the system. All MD simulations were
carried out using the GROMACS 4 programme57 on High-Performance
Computing Infrastructure (HPCI). Electrostatic interactions were calculated using
the particle mesh Ewald method58 with a cutoff radius of 10 Å. Van der Waals
interactions were cutoff at 10Å. The P-LINCS algorithm was employed to
constrain all bond lengths59. After the fully solvated system was energy-minimized,
the system was equilibrated for 100 ps under constant volume and run for 100 ps
under constant pressure and temperature, with positional restraints on protein
heavy atoms and compound atoms. Each production run was conducted for 50 ns
under constant pressure and temperature condition without the positional
restraints. In this procedure, the temperature was maintained at 298K using
velocity rescaling with a stochastic term60 and the pressure was maintained at 1 bar
with the Parrinello–Rahman pressure coupling61, where the time constants for the
temperature and pressure couplings to the bath were 0.3 and 1 ps, respectively. Ten
independent MD simulations were performed with the different initial structures,
and thus we carried out MD simulations of 500 ns in total. All MD runs were
carried out with time steps of 2 fs and snapshots were output every 2 ps to yield 500
snapshots per nanosecond of simulation.
Data and statistical analysis. Data were analysed using GraphPad Prism software
(GraphPad Software). In cell growth inhibition experiments analysis, the curves
were ﬁtted using a nonlinear regression model with a sigmoidal dose response.
Unless otherwise speciﬁed, data displayed are mean±s.d. Pairwise comparisons
between groups (for example, experimental versus control) were made using paired
or unpaired Student’s t-tests as appropriate. Signiﬁcant
probability (P)-values are indicated as ***Po0.001, **Po0.01 and *Po0.05.
Data availability. The authors declare that all the other data supporting the
ﬁndings of this study are available within the article and its Supplementary
Information ﬁles (The original data of Fig. 1a is presented in the Supplementary
Data 1. The uncropped scans of the most important blots are shown in
Supplementary Figs 15–21).
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